Combining immunotherapy and chemotherapy before surgery for borderline resectable pancreatic cancer may improve outcomes, per UCLA Health study.
A UCLA Health study finds that combining immunotherapy with chemotherapy before surgery for borderline resectable pancreatic cancer is safe and may improve long-term outcomes. Results show higher rates of successful tumor removal, longer time before cancer worsens, and extended overall survival compared to historical controls. The combination therapy did not increase adverse side effects or post-operative complications.
April 05, 2024
3 Articles